Core Viewpoint - The SPRUTRITION quercetin capsules, marketed as a dietary supplement for "dissolving nodules," face scrutiny due to questionable efficacy claims and potential violations of advertising laws in China [1][10]. Group 1: Product Issues - The SPRUTRITION quercetin capsules were found to have misleading advertising claims, including the assertion of "dissolving nodules," which lacks clinical evidence [1][10]. - After being taken down from the SPRUTRITION US Spruce live stream, the product was reintroduced under a different name while still promoting the same efficacy claims [1][9]. - The product's online presence includes vague promotional content that suggests health benefits without providing concrete evidence [5][9]. Group 2: Regulatory Concerns - Legal experts highlight that the marketing of quercetin as a treatment for nodules violates multiple articles of the Advertising Law of the People's Republic of China, which prohibits misleading claims and disease treatment assertions [9][10]. - The product's advertising fails to comply with regulations that restrict health claims for dietary supplements, particularly regarding disease prevention and treatment [10][11]. Group 3: Ingredient Efficacy - The product contains several ingredients, including 400mg of PPC, 200mg of quercetin, and others, but there is insufficient clinical evidence to support their effectiveness in treating benign nodules [10][11]. - Quercetin is recognized for its antioxidant properties but lacks high-quality clinical trials demonstrating its efficacy in reducing or eliminating nodules [10][11]. - Other ingredients, such as summer grass extract and cat's claw, have limited research backing their claimed benefits, and their effectiveness remains uncertain [11][12]. Group 4: Company Background - SPRUTRITION is registered under Yunshan Hengmao (Beijing) Enterprise Management Co., Ltd., which was established in November 2017 and operates primarily in business services [12]. - The company holds the SPRUTRITION trademark, with a registration period extending from May 28, 2022, to May 27, 2032 [12].

SPRUTRITION美国云杉直播间，主播正在介绍SPRUTRITION槲皮素胶囊。直播间截图 "产品有什么作用？"记者在直播间留言后，主播并未直接回复，而是告诉记者，"往上面翻，刚刚有家人问过同样的问题，同样的情和况（情况）你看一下 有没有，有的话来跟我说"。记者向上翻动留言，发现有网友在直播间留言"什么结节都可以用吗？"记者注意到，该主播在评论区留言称"PPC每日晚饭后半 小时吃两颗即可，超过一厘米的早晚饭后各吃两颗~"。 也有网友留言咨询："我有甲状结（结节）和乳腺结（结节）可以用吗？"主播同样给出了肯定的答复。 记者点击商品链接发现，商家删除了原本产品介绍中所标示的"玻璃、混合、实性、囊、息、全身节节消"等直白的功效宣称，仅保留了两张暗示功效的宣传 图片，如"人生不纠'结'科学成分配比 小分子好吸收"。在消费者反馈的图片中，该图片右上角仍将产品表述为"云杉小分子PPC结节散胶囊"。 今年5月，新京报刊发《"美国原装、可消结节"胶囊调查：功效存疑，境外电商无此产品》的报道。记者调查发现，作为一款膳食营养补充剂产品，一款名 为SPRUTRITION槲皮素胶囊的"消结"产品存在多重问题：直播间"精准散结"等 ...

Core Viewpoint - SPRUTRITION's quercetin capsules are under investigation for false advertising and misleading health claims, with the product being removed from live sales but still available on other platforms [1][4]. Group 1: Investigation and Regulatory Actions - The Beijing Chaoyang District Market Supervision Administration has initiated an investigation into SPRUTRITION's trademark registration company, Yunshan Hengmao (Beijing) Enterprise Management Co., Ltd., based on allegations of false advertising [1]. - Following a report published on May 28, it was found that the product's claims of treating nodules lack clinical evidence and violate advertising laws [1][2]. Group 2: Product Availability and Marketing Claims - Despite the removal of the product from the SPRUTRITION live sales platform, it remains available on overseas flagship stores, where misleading claims about its efficacy in treating nodules persist [4][5]. - The product's promotional materials on various platforms include phrases suggesting it can "identify and eliminate nodules," which raises concerns about compliance with advertising regulations [3]. Group 3: Company Background - Yunshan Hengmao (Beijing) Enterprise Management Co., Ltd., the applicant for the SPRUTRITION trademark, was established on November 17, 2017, with a registered capital of 2 million RMB, categorizing it as a small and micro enterprise [5].